Action PGEN PRECIGEN, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués Precigen, Inc.

Actions

PGEN

US74017N1054

Temps réel estimé Cboe BZX
Autres places de cotation
 21:10:38 28/06/2024 		Varia. 5j. Varia. 1 janv.
1,505 USD -0,33% Graphique intraday de Precigen, Inc. -2,60% +11,94%
04/06 Transcript : Precigen, Inc. - Special Call
03/06 PRECIGEN, INC. : Stifel Nicolaus optimiste sur le dossier ZM

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting
AQ
Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th
PR
Precigen Reports Full Year 2023 Financial Results and Business Updates
AQ
Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis
PR
Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th
PR
Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
PR
Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission
PR
Precigen Highlights Pipeline Updates to be presented at the 42nd Annual J.P. Morgan Healthcare Conference
AQ
Precigen to Present at the 42nd Annual J.P. Morgan Healthcare Conference
PR
Precigen to Participate in the JMP Securities Hematology and Oncology Summit
PR
Precigen to Participate in the Stifel 2023 Healthcare Conference
PR
Precigen to Participate in Upcoming Leading Investor and Industry Conferences
PR
Precigen Reports Second Quarter and First Half 2023 Financial Results and Provides Update on Portfolio Prioritization and Capital Allocation Strategies to Extend Projected Cash Runway into 2025
AQ
Precigen Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval
PR
Precigen to Announce Second Quarter and First Half 2023 Financial Results on August 9th
PR
Precigen Receives Breakthrough Therapy Designation for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis
AQ
Precigen Receives Breakthrough Therapy Designation for PRGN-2012 AdenoVerse™ Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis
PR
PRECIGEN, INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
AQ
Precigen Reports First Quarter 2023 Financial Results and Business Updates
AQ
PRECIGEN, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)
AQ
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action PGEN
  4. Actualités Precigen, Inc.
  5. Communiqués